0.50 / AMA PRA Category 1 Credit(s)TM 0.50 / CE for Pharmacists (0.05 CEUs)
Jointly provided by Haymarket Medical Education and the University of Wisconsin-Madison Division of Pharmacy Professional Development
Supported by an educational grant from Ironwood Pharmaceuticals, Inc.
The most common form of inflammatory arthritis, gout is a rheumatic disease resulting from the deposition of uric acid crystals (monosodium urate) in body tissues and fluids. Increases in gout prevalence have been linked to the rising rates of chronic health conditions associated with hyperuricemia, including hypertension, metabolic syndrome, type 2 diabetes mellitus, obesity, and chronic kidney disease. The interplay of gout and comorbid diseases puts patients with untreated or undertreated gout at risk for irreversible joint damage and a host of other potentially life-threatening complications.
In this educational activity, a family physician and a rheumatologist discuss the current landscape of gout management. Key differences between evidence-based treatment guidelines from the American College of Rheumatology and the American College of Physicians are discussed, as are the implications for practice. The faculty review available options for urate-lowering therapy as well as strategies for keeping patients with gout engaged in long-term treatment.
Family medicine and internal medicine (IM) clinicians (MDs/DOs, physician assistants [PAs], nurse practitioners [NPs]), pharmacists, rheumatologists, and nephrologists
After completing the activity, the participant should be better able to:
Describe the common comorbidities of gout and implications for treatment
Review key differences in evidence-based guidelines for gout management
Conflict Of Interest Disclosure Policy
It is the policy of the University of Wisconsin-Madison ICEP and Haymarket Medical Education that the faculty, authors, planners, and other persons who may influence the content of this CE activity to disclose all relevant financial relationships with commercial interests in order to allow CE staff to identify and resolve any potential conflicts of interest. Faculty must also disclose any planned discussion of unlabeled/unapproved uses of drugs or devices during their presentation(s). For this educational activity, all conflicts of interest have been resolved and detailed discussions are listed below.
Paul Doghramji, MD Family Physician Collegeville Family Practice Collegeville, PA
Dr. Doghramji has nothing to disclose.
Kenneth Saag, MD Jane Knight Lowe Professor of Medicine Vice Chair, Department of Medicine Director, Center for Outcomes and Effectiveness Research and Education (COERE) Director, Center for Education and Research on Therapeutics (CERTs) Director, Center of Research Translation (CORT) in Gout and Hyperuricemia UAB School of Medicine Birmingham, AL
Dr. Saag receives consulting fees and provides contracted research for Ironwood Pharmaceuticals, AstraZeneca, Horizon Pharma, SOBI, and Takeda.
Accredited Provider Disclosures
The staff of Haymarket Medical Education have nothing to disclose with regard to commercial support.
The staff of the University of Wisconsin-Madison Interprofessional Continuing Education Partnership (ICEP) have nothing to disclose with regard to commercial support.
Publishing Staff Disclosures
Krista Sierra and Susan Basilico of Haymarket Medical Education have nothing to disclose with regard to commercial support.
AMA PRA Category 1 Credit(s)TM
Haymarket Medical Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Haymarket Medical Education designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)TM . Physicians should only claim those credits commensurate with the extent of their participation in the activity.
CE for Pharmacists
In support of improving patient care, the University of Wisconsin-Madison ICEP is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
A total of 0.50 hours (0.05 CEUs) of pharmacy CE credit will be provided for successful completion of this knowledge-based program. To receive CE credit, you must complete the program; complete the evaluation; and complete the post-test with a minimum score of 70%. Verification of completion will be provided to NABP within 60 days of completion of this program. No credit will be provided 60 days after this program expires. Universal Program #JA0000359-9999-19-025-H01-P.
Disclosure of Unlabeled Use
This CME activity will not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing medical education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options for a specific patient's medical condition.
The opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Haymarket Medical Education, the University of Wisconsin-Madison, or Ironwood Pharmaceuticals. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
To obtain credit, a score of 70% or better on the post-test is required. Please proceed until you have successfully completed this activity and completed the post-test and evaluation, and for CME credit only, that you have received a digital copy of your credit certificate. Your online certificate will be saved on myCME within your Profile/Exam History, which you can access at any time.
For CPE credit, your credit will automatically be provided to NABP. Please verify that your credit has been recorded by checking your NABP profile after 1 business day.